Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder

NCT02178241 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02178241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02178241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
December 11, 2014
Completion date
July 11, 2019
Enrollment
26 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic ureter carcinoma, metastatic urethral carcinoma, stage iii bladder urothelial carcinoma ajcc v6 and v7, stage iii ureter cancer ajcc v7, stage iii urethral cancer ajcc v7, stage iv bladder urothelial carcinoma ajcc v7, stage iv ureter cancer ajcc v7, stage iv urethral cancer ajcc v7, ureter urothelial carcinoma, urethral urothelial carcinoma